Healthcare services provider Ambry Genetics has launched paired RNA and DNA testing for hereditary cancer.

The +RNAinsight test will screen the RNA transcript for 18 genes, including BRCA genes.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It works in tandem with Ambry Genetics’ DNA testing to identify patients with or at-risk of hereditary cancer who might otherwise go undiagnosed.

The Paired DNA and RNA testing will improve variant detection and classification, lower variants of unknown significance in real-time and provide accurate results to inform patient care.

Ambry said a prospective analysis of the first 2,500 patients tested with paired RNA and DNA hereditary cancer for up to 18 genes, sent from pilot clinical sites, led to an increase in the diagnostic yield of around 7%.

The +RNAinsight test, available through doctors and genetic counsellors across the US, decreased the number of inconclusive results across the included cancer risk genes by about 5% relative to DNA testing alone.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Tests such as +RNAinsight require 1 PAXgene blood tube for RNA analysis and purple top (EDTA) tube for DNA testing.

Ambry Genetics CEO Aaron Elliott said: “We developed paired RNA and DNA testing to provide more accurate and conclusive results that patients and doctors can act on.

“With +RNAinsight, we not only identify mutations that DNA testing alone would miss, we also provide answers for patients who have been dealing with inconclusive results for years.”

Earlier this year, Ambry Genetics presented a study to demonstrate that RNA genetic testing (RGT) in hereditary cancer improves variant classification and patient management.

Study findings suggest that RGT will impact medical management in at least 1 in 50 patients who have first undergone DNA genetic testing.